ESR2
Estrogen receptor beta
As of the edition of 20 October 2026, ESR2 (estrogen receptor beta, UniProt Q92731) has 27 drugs tested at it and 27 companies on the list, 5 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q92731
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 39
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Digestive system; Nutrition and metabolism; Bones, joints and muscles; Mental health
- Registered trials of its drugs
- 357
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 14 |
| Active | 3 |
| Went quiet | 3 |
| Stopped | 5 |
| Withdrawn from market | 2 |
| Total | 27 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Estrogen | Active | Phase 4 | none listed |
| Estrogens, conjugated | Marketed | Phase 4 | none listed |
| Chlorotrianisene | Marketed | Phase 3 | none listed |
| Estramustine phosphate | Marketed | Phase 3 | none listed |
| Toremifene | Marketed | Phase 4 | none listed |
| Bazedoxifene | Marketed | Phase 4 | Ends 2027 |
| Estetrol anhydrous | Marketed | Phase 4 | none listed |
| Estramustine | Marketed | Phase 3 | none listed |
| Estriol | Marketed | Phase 3 | none listed |
| Arzoxifene | Went quiet | Phase 4 | none listed |
| AUS-131 | Active | Phase 2 | none listed |
| Lasofoxifene | Withdrawn from market | Phase 3 | none listed |
12 of 27 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 6 |
| Engaged | 5 |
| Undetermined | 11 |
| Total on the list | 27 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Teva | Route B |
| Duchesnay | Route B |
The other 24 companies at ESR2
In the product27 companies in all; 24 are not named here, and no score is.
See the 27 companies at ESR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.